Heads up!
We’ve moved some things around. Take a quick tour to learn what has changed.
Take the tour
No thanks!
Leucine
Identification
- Name
- Leucine
- Accession Number
- DB00149
- Description
An essential branched-chain amino acid important for hemoglobin formation.
- Type
- Small Molecule
- Groups
- Investigational, Nutraceutical
- Structure
Structure for Leucine (DB00149)
- Weight
- Average: 131.1729
Monoisotopic: 131.094628665 - Chemical Formula
- C6H13NO2
- Synonyms
- (2S)-2-Amino-4-methylpentanoic acid
- (2S)-alpha-2-Amino-4-methylvaleric acid
- (2S)-alpha-Leucine
- (S)-(+)-Leucine
- (S)-Leucine
- 2-Amino-4-methylvaleric acid
- L
- L-Leucin
- L-Leucine
- L-Leuzin
- Leu
- Leucine
- External IDs
- FEMA NO. 3297
Pharmacology
- Indication
Indicated to assist in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress.
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
An essential amino acid. (Claim) Leucine helps with the regulation of blood-sugar levels, the growth and repair of muscle tissue (such as bones, skin and muscles), growth hormone production, wound healing as well as energy regulation. It can assist to prevent the breakdown of muscle proteins that sometimes occur after trauma or severe stress. It may also be beneficial for individuals with phenylketonuria - a condition in which the body cannot metabolize the amino acid phenylalanine
- Mechanism of action
This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.
Target Actions Organism UProbable leucine--tRNA ligase, mitochondrial Not Available Humans UBranched-chain-amino-acid aminotransferase, mitochondrial Not Available Humans UBranched-chain-amino-acid aminotransferase, cytosolic Not Available Humans ULeucine carboxyl methyltransferase 2 Not Available Humans ULeucine carboxyl methyltransferase 1 Not Available Humans ULeucine--tRNA ligase, cytoplasmic Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Product Ingredients
Ingredient UNII CAS InChI Key L-Leucine hydrochloride N39KV97633 760-84-9 XKZZNHPZEPVUQK-JEDNCBNOSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Leucine (182.5 mg) + Alanine (520 mg) + Arginine (290 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + Isoleucine (150 mg) + L-Lysine (145 mg) + Magnesium chloride (25.5 mg) + Methionine (100 mg) + Phenylalanine (140 mg) + Proline (170 mg) + Serine (125 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Tyrosine (10 mg) + Valine (145 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2015-08-05 Canada 
2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Clinimix L-Leucine hydrochloride (155 mg) + Alanine (520 mg) + Arginine (260 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (520 mg) + Histidine (110 mg) + Isoleucine (120 mg) + L-Lysine hydrochloride (145 mg) + Magnesium chloride (25.5 mg) + Methionine (145 mg) + Phenylalanine hydrochloride (155 mg) + Proline (105 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Tyrosine (10 mg) + Valine (115 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1993-12-31 2015-08-05 Canada 2.5% Travasol Amino Acid Injection Without Electrolytes In 10% Dextrose Quickmix L-Leucine hydrochloride (155 mg) + Alanine (520 mg) + Arginine (260 mg) + Dextrose, unspecified form (10 g) + Glycine (520 mg) + Histidine (110 mg) + Isoleucine (120 mg) + L-Lysine hydrochloride (195 mg) + Methionine (195 mg) + Phenylalanine hydrochloride (155 mg) + Proline (105 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Tyrosine (10 mg) + Valine (115 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1995-12-31 2007-08-02 Canada 2.5%travasol Amino Acid InJ.W.eleC.W.25%dex Leucine (182.5 mg) + Alanine (520 mg) + Arginine (290 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + Isoleucine (150 mg) + L-Lysine (145 mg) + Magnesium chloride (25.5 mg) + Methionine (100 mg) + Phenylalanine (140 mg) + Proline (170 mg) + Serine (125 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Tyrosine (10 mg) + Valine (145 mg) Liquid Intravenous Clintec Nutrition Company 1996-07-30 1998-08-13 Canada 2.75% Travas. Amino Acid InJ.W.elecw.25%dex Leucine (201 mg) + Alanine (570 mg) + Arginine (316 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + Isoleucine (165 mg) + L-Lysine (159.5 mg) + Magnesium chloride (51 mg) + Methionine (110 mg) + Phenylalanine (154 mg) + Proline (187 mg) + Serine (137.5 mg) + Sodium acetate (215.5 mg) + Sodium chloride (112 mg) + Threonine (115.5 mg) + Tryptophan (49.5 mg) + Tyrosine (11 mg) + Valine (159.5 mg) Liquid Intravenous Clintec Nutrition Company 1996-07-30 1998-08-13 Canada 2.75% Travasol Amino Acid Injection With Electrolytes In 25% Dextrose Quickmix L-Leucine hydrochloride (170 mg) + Alanine (570 mg) + Arginine (285 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (570 mg) + Histidine (120.5 mg) + Isoleucine (131.5 mg) + L-Lysine hydrochloride (159 mg) + Magnesium chloride (51 mg) + Methionine (159 mg) + Phenylalanine hydrochloride (170 mg) + Proline (115 mg) + Sodium acetate (215.5 mg) + Sodium chloride (112 mg) + Threonine (115 mg) + Tryptophan (49.5 mg) + Tyrosine (11 mg) + Valine (126 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-02-02 2007-08-02 Canada 2.75% Travasol Amino Acid Injection With Electrolytes In 5% Dextrose Quickmix L-Leucine hydrochloride (170 mg) + Alanine (570 mg) + Arginine (285 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (215.5 mg) + Glycine (570 mg) + Histidine (120.5 mg) + Isoleucine (131.5 mg) + L-Lysine hydrochloride (159 mg) + Magnesium chloride (51 mg) + Methionine (159 mg) + Phenylalanine hydrochloride (170 mg) + Proline (115 mg) + Sodium acetate (256 mg) + Sodium chloride (112 mg) + Threonine (115 mg) + Tryptophan (49.5 mg) + Tyrosine (11 mg) + Valine (126 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1993-12-31 2007-08-02 Canada 2.75%travasol Amino Acid InJ.W.eleC.W.5%dex. Leucine (201 mg) + Alanine (570 mg) + Arginine (316 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + Isoleucine (165 mg) + L-Lysine (159.5 mg) + Magnesium chloride (51 mg) + Methionine (110 mg) + Phenylalanine (154 mg) + Proline (187 mg) + Serine (137.5 mg) + Sodium acetate (215 mg) + Sodium chloride (112 mg) + Threonine (115.5 mg) + Tryptophan (49.5 mg) + Tyrosine (11 mg) + Valine (159.5 mg) Liquid Intravenous Clintec Nutrition Company 1996-12-31 1999-08-10 Canada 20% Prosol Leucine (1.08 g) + Alanine (2.76 g) + Arginine (1.96 g) + Aspartic acid (0.6 g) + D-Methionine (0.76 g) + Glutamic acid (1.02 g) + Glycine (2.06 g) + Histidine (1.18 g) + Isoleucine (1.08 g) + L-Lysine (1.35 g) + Methionine (0.76 g) + Phenylalanine (1 g) + Proline (1.34 g) + Serine (1.02 g) + Threonine (0.98 g) + Tryptophan (0.32 g) + Tyrosine (0.05 g) + Valine (1.44 g) Liquid Intravenous Baxter Laboratories 1996-10-09 Not applicable Canada 4.25% Amino Acid Injection Without Electrolytes In 20% Dextrose Quickmix L-Leucine hydrochloride (263 mg) + Alanine (880 mg) + Arginine (440 mg) + Dextrose, unspecified form (20 g) + Glycine (880 mg) + Histidine (186 mg) + Isoleucine (203 mg) + L-Lysine hydrochloride (246 mg) + Methionine (246 mg) + Phenylalanine hydrochloride (263 mg) + Proline (178 mg) + Threonine (178 mg) + Tryptophan (76 mg) + Tyrosine (17 mg) + Valine (195 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1995-12-31 2007-08-02 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ASCE plus Derma Signal Kit SRLV S Leucine (0.0008 mg/20mg) + Leucine (0.0002 g/5.0mL) + Isoleucine (0.0006 mg/20mg) + Isoleucine (0.0001 g/5.0mL) Kit Topical Exocobio Inc. 2019-03-01 Not applicable US 
ASCE plus Derma Signal Kit SRLV S Leucine (0.0008 mg/20mg) + Leucine (0.0002 g/5.0mL) + Isoleucine (0.0006 mg/20mg) + Isoleucine (0.0001 g/5.0mL) Kit Topical Exocobio Inc. 2019-03-01 Not applicable US Clinimix Leucine (6.20 g/2L) + Alanine (17.60 g/2L) + Arginine (9.78 g/2L) + Calcium chloride dihydrate (0.66 g/2L) + D-glucose monohydrate (300.00 g/2L) + Dipotassium phosphate (5.22 g/2L) + Glycine (8.76 g/2L) + Histidine (4.08 g/2L) + Isoleucine (5.10 g/2L) + L-Lysine (4.93 g/2L) + Magnesium chloride hexahydrate (1.02 g/2L) + Methionine (3.40 g/2L) + Phenylalanine (4.76 g/2L) + Proline (5.78 g/2L) + Serine (4.25 g/2L) + Sodium acetate trihydrate (5.94 g/2L) + Sodium chloride (1.54 g/2L) + Threonine (3.57 g/2L) + Tryptophan (1.53 g/2L) + Tyrosine (0.34 g/2L) + Valine (4.93 g/2L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US Clinimix Leucine (2.01 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (75.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Lysine (2.00 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US Clinimix Leucine (2.01 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (100.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Lysine (2.00 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US Primene Leucine (2.5 g/250mL) + Alanine (2 g/250mL) + Arginine (2.1 g/250mL) + Aspartic acid (1.5 g/250mL) + Cysteine (0.47 g/250mL) + Glutamic acid (2.5 g/250mL) + Glycine (1 g/250mL) + Histidine (0.95 g/250mL) + Isoleucine (1.675 g/250mL) + L-Lysine (2.75 g/250mL) + Methionine (0.6 g/250mL) + Ornithine hydrochloride (0.8 g/250mL) + Phenylalanine (1.05 g/250mL) + Proline (0.75 g/250mL) + Serine (1 g/250mL) + Taurine (0.15 g/250mL) + Threonine (0.9 g/250mL) + Tryptophan (0.5 g/250mL) + Tyrosine (0.11 g/250mL) + Valine (1.9 g/250mL) Injection, solution Intravenous Baxter Healthcare Corporation 2017-11-22 2019-05-31 US Synthamin Leucine (7.30 g/1000mL) + Alanine (20.70 g/1000mL) + Arginine (11.50 g/1000mL) + Glycine (10.30 g/1000mL) + Histidine (4.80 g/1000mL) + Isoleucine (6 g/1000mL) + L-Lysine (5.80 g/1000mL) + Methionine (4 g/1000mL) + Phenylalanine (5.60 g/1000mL) + Proline (6.80 g/1000mL) + Serine (5 g/1000mL) + Threonine (4.20 g/1000mL) + Tryptophan (1.80 g/1000mL) + Tyrosine (400 mg/1000mL) + Valine (5.80 g/1000mL) Injection, solution Intravenous Baxter Healthcare Corporation 2017-11-03 2020-06-30 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as leucine and derivatives. These are compounds containing leucine or a derivative thereof resulting from reaction of leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Leucine and derivatives
- Alternative Parents
- L-alpha-amino acids / Methyl-branched fatty acids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Alpha-amino acid / Amine / Amino acid / Branched fatty acid / Carbonyl group / Carboxylic acid / Fatty acid / Fatty acyl / Hydrocarbon derivative
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- proteinogenic amino acid, L-alpha-amino acid, leucine, pyruvate family amino acid (CHEBI:15603) / Common amino acids (C00123)
Chemical Identifiers
- UNII
- GMW67QNF9C
- CAS number
- 61-90-5
- InChI Key
- ROHFNLRQFUQHCH-YFKPBYRVSA-N
- InChI
- InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1
- IUPAC Name
- (2S)-2-amino-4-methylpentanoic acid
- SMILES
- CC(C)C[[email protected]](N)C(O)=O
References
- Synthesis Reference
Takayasu Tsuchida, Haruo Momose, Yoshio Hirose, "Process for producing L-leucine." U.S. Patent US3970519, issued February, 1975.
US3970519- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000687
- KEGG Drug
- D00030
- KEGG Compound
- C00123
- PubChem Compound
- 6106
- PubChem Substance
- 46507163
- ChemSpider
- 5880
- BindingDB
- 50219348
- 6308
- ChEBI
- 57427
- ChEMBL
- CHEMBL291962
- ZINC
- ZINC000003645145
- PharmGKB
- PA450197
- PDBe Ligand
- LEU
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Leucine
- MSDS
- Download (72.6 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Illness, Critical / Starvation 1 4 Recruiting Supportive Care Illness, Critical 1 4 Terminated Supportive Care Cancer-related Malnutrition 1 4 Terminated Supportive Care Parenteral Nutrition (No Primary Condition Studied) 1 4 Withdrawn Supportive Care Malnutrition 1 3 Completed Treatment General Surgery / Parenteral Nutrition 1 3 Completed Treatment Illness, Critical 1 3 Completed Treatment Infant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / Sepsis 1 3 Completed Treatment Parents 2 3 Recruiting Treatment General Surgery / Parenteral Feeding 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Gallipot
- Vitaflo
- Dosage Forms
Form Route Strength Liquid Intravenous Solution Intravenous 0.25 g/mL Tablet Oral 45 mg Injection, solution Intravenous 2.5 g/500mL Solution Intravenous 2.453 g Solution, concentrate Intravenous 5 g Solution Intravenous 10.4 g/L Solution Intravenous 5 g Solution Intravenous 4.15 g Solution Intravenous 1.566 g Kit Topical Solution Intraperitoneal 951 mg/L Injection, solution Intravenous Solution Intravenous 0.69 % Solution Intravenous 0.59 % Solution Intravenous 1.03 g Injection, emulsion Intravenous Injection Intravenous 110 g Injection Intravenous 165 g Injection Intravenous 220 g Injection Intravenous 275 g Injection Intravenous 107 g Injection Intravenous 143 g Injection Intravenous 178 g Solution 16 g/L Injection, solution, concentrate Intravenous Emulsion Intravenous 1.83 g Injection Intravenous 1.03 g Injection, emulsion Intravenous 1.6 g/100mL Injection, emulsion; injection, solution Intravenous 3.2 g/100mL Emulsion Intravenous 20 mg Emulsion Intravenous 16 g Liquid Hemodialysis Solution Intraperitoneal 510 mg/l Injection, emulsion Intravenous 1.6 g Injection Intravenous 2.27 g/l Injection Intravenous 4.12 g/l Emulsion Intravenous 4 g Solution Intravenous 7.14 g Solution Intravenous 9.52 g Solution Intravenous 11.9 g Emulsion Intravenous 6.41 g Emulsion Intravenous 9.61 g Emulsion Intravenous 12.82 g Solution Intravenous 8.24 g Solution Intravenous 12.36 g Solution Intravenous 16.48 g Emulsion Intravenous Emulsion Intravenous 3 g Injection, solution Intravenous 0.69 % Injection, solution Intravenous 0.59 % Injection, solution Intravenous 0.9 % Injection, solution Intravenous 0.56 % Injection, solution Intravenous 0.49 % Injection, solution Intravenous 0.76 % Solution Intravenous Solution 3.2 g/100mL Solution 1.6 g/100mL Injection Intravenous 0.67 g/100ml Solution Parenteral 3 g/100ml Emulsion Parenteral 50 g Injection, solution Intravenous 0.76 g/100mL Injection Intravenous Solution Intravenous 434 mg Solution Intravenous 594 mg Solution Intravenous 12 g/L Solution Intravenous 16 g/L Solution Intravenous 5.1 g/16g N - Prices
Unit description Cost Unit Leucine powder 1.62USD each L-leucine powder 0.28USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 293 °C PhysProp water solubility 2.15E+004 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -1.52 HANSCH,C ET AL. (1995) pKa 2.35 (at 13 °C) KORTUM,G ET AL (1961) - Predicted Properties
Property Value Source Water Solubility 69.8 mg/mL ALOGPS logP -1.8 ALOGPS logP -1.6 ChemAxon logS -0.27 ALOGPS pKa (Strongest Acidic) 2.79 ChemAxon pKa (Strongest Basic) 9.52 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 63.32 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 34.17 m3·mol-1 ChemAxon Polarizability 14.16 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Download (8.19 KB)
- Spectra
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Leucine-trna ligase activity
- Specific Function
- Not Available
- Gene Name
- LARS2
- Uniprot ID
- Q15031
- Uniprot Name
- Probable leucine--tRNA ligase, mitochondrial
- Molecular Weight
- 101975.43 Da
References
- Ma JJ, Zhao MW, Wang ED: Split leucine-specific domain of leucyl-tRNA synthetase from the hyperthermophilic bacterium Aquifex aeolicus. Biochemistry. 2006 Dec 12;45(49):14809-16. [PubMed:17144674]
- Zhu B, Zhao MW, Eriani G, Wang ED: A present-day aminoacyl-tRNA synthetase with ancestral editing properties. RNA. 2007 Jan;13(1):15-21. Epub 2006 Nov 9. [PubMed:17095543]
- Vu MT, Martinis SA: A unique insert of leucyl-tRNA synthetase is required for aminoacylation and not amino acid editing. Biochemistry. 2007 May 1;46(17):5170-6. Epub 2007 Apr 4. [PubMed:17407263]
- Hsu JL, Rho SB, Vannella KM, Martinis SA: Functional divergence of a unique C-terminal domain of leucyl-tRNA synthetase to accommodate its splicing and aminoacylation roles. J Biol Chem. 2006 Aug 11;281(32):23075-82. Epub 2006 Jun 14. [PubMed:16774921]
- Lue SW, Kelley SO: A single residue in leucyl-tRNA synthetase affecting amino acid specificity and tRNA aminoacylation. Biochemistry. 2007 Apr 17;46(15):4466-72. Epub 2007 Mar 23. [PubMed:17378584]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- L-valine transaminase activity
- Specific Function
- Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. May also function as a transporter of branched chain alpha-keto acids.
- Gene Name
- BCAT2
- Uniprot ID
- O15382
- Uniprot Name
- Branched-chain-amino-acid aminotransferase, mitochondrial
- Molecular Weight
- 44287.445 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Berger BJ, English S, Chan G, Knodel MH: Methionine regeneration and aminotransferases in Bacillus subtilis, Bacillus cereus, and Bacillus anthracis. J Bacteriol. 2003 Apr;185(8):2418-31. [PubMed:12670965]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- L-valine transaminase activity
- Specific Function
- Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine.
- Gene Name
- BCAT1
- Uniprot ID
- P54687
- Uniprot Name
- Branched-chain-amino-acid aminotransferase, cytosolic
- Molecular Weight
- 42965.815 Da
References
- Chen CD, Huang TF, Lin CH, Guan HH, Hsieh YC, Lin YH, Huang YC, Liu MY, Chang WC, Chen CJ: Purification, crystallization and preliminary X-ray crystallographic analysis of branched-chain aminotransferase from Deinococcus radiodurans. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jun 1;63(Pt 6):492-4. Epub 2007 May 5. [PubMed:17554170]
- Saito M, Nishimura K, Wakabayashi S, Kurihara T, Nagata Y: Purification of branched-chain amino acid aminotransferase from Helicobacter pylori NCTC 11637. Amino Acids. 2007 Sep;33(3):445-9. Epub 2006 Nov 2. [PubMed:17077963]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Trna methyltransferase activity
- Specific Function
- Probable S-adenosyl-L-methionine-dependent methyltransferase that acts as a component of the wybutosine biosynthesis pathway. Wybutosine is a hyper modified guanosine with a tricyclic base found at...
- Gene Name
- LCMT2
- Uniprot ID
- O60294
- Uniprot Name
- tRNA wybutosine-synthesizing protein 4
- Molecular Weight
- 75601.095 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- S-adenosylmethionine-dependent methyltransferase activity
- Specific Function
- Methylates the carboxyl group of the C-terminal leucine residue of protein phosphatase 2A catalytic subunits to form alpha-leucine ester residues.
- Gene Name
- LCMT1
- Uniprot ID
- Q9UIC8
- Uniprot Name
- Leucine carboxyl methyltransferase 1
- Molecular Weight
- 38378.695 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Leucine-trna ligase activity
- Specific Function
- Catalyzes the specific attachment of an amino acid to its cognate tRNA in a two step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end ...
- Gene Name
- LARS
- Uniprot ID
- Q9P2J5
- Uniprot Name
- Leucine--tRNA ligase, cytoplasmic
- Molecular Weight
- 134465.155 Da
References
- Ma JJ, Zhao MW, Wang ED: Split leucine-specific domain of leucyl-tRNA synthetase from the hyperthermophilic bacterium Aquifex aeolicus. Biochemistry. 2006 Dec 12;45(49):14809-16. [PubMed:17144674]
- Karkhanis VA, Boniecki MT, Poruri K, Martinis SA: A viable amino acid editing activity in the leucyl-tRNA synthetase CP1-splicing domain is not required in the yeast mitochondria. J Biol Chem. 2006 Nov 3;281(44):33217-25. Epub 2006 Sep 6. [PubMed:16956879]
- Vu MT, Martinis SA: A unique insert of leucyl-tRNA synthetase is required for aminoacylation and not amino acid editing. Biochemistry. 2007 May 1;46(17):5170-6. Epub 2007 Apr 4. [PubMed:17407263]
- Hsu JL, Rho SB, Vannella KM, Martinis SA: Functional divergence of a unique C-terminal domain of leucyl-tRNA synthetase to accommodate its splicing and aminoacylation roles. J Biol Chem. 2006 Aug 11;281(32):23075-82. Epub 2006 Jun 14. [PubMed:16774921]
- Dohm JC, Vingron M, Staub E: Horizontal gene transfer in aminoacyl-tRNA synthetases including leucine-specific subtypes. J Mol Evol. 2006 Oct;63(4):437-47. Epub 2006 Sep 4. [PubMed:16955236]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Transporter activity
- Specific Function
- Sodium-independent transporter that mediates the update of aromatic acid. Can function as a net efflux pathway for aromatic amino acids in the basosolateral epithelial cells (By similarity).
- Gene Name
- SLC16A10
- Uniprot ID
- Q8TF71
- Uniprot Name
- Monocarboxylate transporter 10
- Molecular Weight
- 55492.07 Da
References
- Kim DK, Kanai Y, Matsuo H, Kim JY, Chairoungdua A, Kobayashi Y, Enomoto A, Cha SH, Goya T, Endou H: The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics. 2002 Jan;79(1):95-103. [PubMed:11827462]
- Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H: Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biol Chem. 2001 May 18;276(20):17221-8. Epub 2001 Feb 20. [PubMed:11278508]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Transporter activity
- Specific Function
- Very active and specific thyroid hormone transporter. Stimulates cellular uptake of thyroxine (T4), triiodothyronine (T3), reverse triiodothyronine (rT3) and diidothyronine. Does not transport Leu,...
- Gene Name
- SLC16A2
- Uniprot ID
- P36021
- Uniprot Name
- Monocarboxylate transporter 8
- Molecular Weight
- 59510.86 Da
References
- Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ: Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem. 2003 Oct 10;278(41):40128-35. Epub 2003 Jul 18. [PubMed:12871948]
Drug created on June 13, 2005 07:24 / Updated on September 03, 2020 19:00
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg","ThriveHealth-1.jpg":"/assets/ads/ThriveHealth-1-fe42678c71bf2ec7d508fde77efbe9f0aa868c5fa03bd39a7e1c97cefac0fa9d.jpg","ThriveHealth-2.jpg":"/assets/ads/ThriveHealth-2-32bb14bb00de8a1b2efc2a51ce37f490c01e76dac7b9c09b6b831c50640b6567.jpg","ThriveHealth-3.jpg":"/assets/ads/ThriveHealth-3-e184eae1745f8aa22525b294b761ee89f5a854a434d50e5d6d37c0b77f2cf523.jpg","ThriveHealth-4.jpg":"/assets/ads/ThriveHealth-4-218f710e6d20831711d0920e585b986217c38f38d9849b8dd32bb56f68d2eea9.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates